Good Clinical Practice in 2026: What ICH E6(R3) Means for Modern Clinical Trials

Sep 11, 2026

For decades, Good Clinical Practice (GCP) has provided the ethical and scientific foundation for conducting clinical trials involving human participants.

But clinical research has changed dramatically.

Today's trials may involve decentralized elements, electronic health records, wearable technologies, electronic consent, remote assessments, centralized monitoring, real-world data and increasingly complex digital ecosystems.

The regulatory framework therefore needed to evolve as well.

That evolution is reflected in ICH E6(R3)—the third revision of the International Council for Harmonisation's Good Clinical Practice guideline.

The change is significant.

E6(R3) does not simply ask clinical research organizations to generate more documentation or introduce additional procedural layers. It emphasizes something more fundamental:

Quality should be designed into a clinical trial from the beginning, risks should be managed proportionately, and trial processes should focus on what truly matters for participant protection and the reliability of results.

For sponsors, CROs, investigators, CRAs, CRCs and other clinical research professionals, this represents an important evolution in how we think about GCP.

First: What Is Good Clinical Practice?

Good Clinical Practice is an international ethical, scientific and quality standard for clinical trials involving human participants.

At its core, GCP seeks to ensure two things:

1. The rights, safety and well-being of trial participants are protected.

2. Clinical trial results are reliable.

These principles remain fundamental under E6(R3). The FDA describes the revised guideline as maintaining a strong focus on participant protection and reliable trial results while incorporating flexible, risk-based approaches and supporting innovations in trial design, conduct and technology.

So E6(R3) does not change the fundamental purpose of GCP.

It modernizes how that purpose can be achieved.

Why Was E6 Revised Again?

The original ICH E6 guideline was developed in an era when clinical trials were predominantly site-based, paper-driven and operationally very different from contemporary studies.

E6(R2) subsequently strengthened areas such as sponsor oversight and risk-based quality management.

But the research environment continued to evolve.

Modern clinical trials can now involve:

Electronic Data Capture (EDC)
eConsent
eCOA and ePRO
Wearable and sensor technologies
Remote trial activities
Centralized monitoring
Electronic health records
Real-world data
Pragmatic trial designs
Decentralized trial elements
Multiple technology and service providers
Complex global data flows

A GCP framework for this environment needs to protect participants and assure reliable results without forcing every trial into the same operational model.

E6(R3) therefore places greater emphasis on flexibility, proportionality and fitness for purpose.

1. Quality by Design: Quality Begins Before the Trial Starts

Perhaps one of the most important concepts reinforced by E6(R3) is Quality by Design (QbD).

Traditional approaches can sometimes create the impression that quality is something checked later:

Design the trial.

Run the trial.

Monitor it.

Audit it.

Correct the problems.

E6(R3), building on ICH E8(R1), encourages a more proactive philosophy.

What if we identify the factors most important to trial quality before the study begins—and design the trial to protect them?

This means considering during study planning:

Which endpoints are critical?
Which data are essential to answering the research question?
Which processes directly affect participant safety?
Which protocol requirements could create unnecessary complexity?
What operational risks could undermine reliability?
Which procedures genuinely need intensive controls?

Quality therefore becomes a property of trial design, rather than merely the outcome of monitoring and inspection.

A poorly designed trial cannot always be rescued by excellent monitoring.

2. Identify What Is Critical to Quality

Not every piece of trial information carries the same importance.

Not every operational deviation carries the same risk.

E6(R3) encourages attention to factors critical to quality—those characteristics of a trial whose integrity is fundamental to protecting participants and producing reliable results.

Examples might include:

Appropriate informed consent
Correct participant eligibility
Administration of the correct investigational intervention
Accurate primary endpoint assessment
Timely reporting of critical safety information
Maintenance of randomization and blinding where applicable

This leads to an important operational question:

Are our resources focused on the activities that matter most?

Clinical research quality should not be measured simply by the volume of documentation generated.

It should be measured by whether the trial's critical processes and data are appropriately controlled.

3. Proportionality: Not Every Risk Requires the Same Response

Another central concept is proportionality.

The intensity of trial processes should be proportionate to:

Risks to participants
Importance of the data being generated
Characteristics of the trial
Complexity of the intervention
Existing knowledge about the intervention

This has practical implications across clinical operations, monitoring, data management, quality assurance and vendor oversight.

For example, applying the same monitoring strategy to every trial regardless of complexity or risk may consume resources without necessarily improving participant protection or data reliability.

A proportionate approach asks:

Where could something go wrong?

How important would that failure be?

How likely is it to occur?

What controls are appropriate?

That is a more sophisticated quality strategy than attempting to eliminate every conceivable operational variation.

4. Risk-Based Quality Management Becomes More Meaningful

Risk-based quality management is not new to clinical research.

However, E6(R3) further embeds risk-based thinking throughout the trial lifecycle.

Sponsors should identify risks that could affect critical-to-quality factors and implement appropriate controls.

This can influence:

Monitoring strategy
Data review
Site oversight
Vendor oversight
Safety surveillance
Quality tolerance considerations
Issue escalation
Corrective and preventive actions

The key is that risk management should be dynamic.

Risks identified during planning may change as the trial progresses.

For example, emerging recruitment patterns, protocol deviations, safety findings or data-quality trends may indicate that oversight needs to be adjusted.

Risk management therefore should not become a document prepared at study start and forgotten in the Trial Master File.

It should inform actual decision-making.

5. Monitoring Is No Longer Synonymous With Checking Everything

For many years, clinical monitoring was strongly associated with extensive on-site source data verification.

Modern trial oversight has increasingly moved toward risk-based monitoring, combining approaches such as:

On-site monitoring
Remote monitoring
Centralized monitoring
Targeted source data review
Data analytics
Key risk indicators
Trend analysis

The appropriate combination depends on the study.

This does not mean monitoring becomes less rigorous.

It means monitoring becomes more focused.

A CRA's value should not be measured by how many data fields are manually checked.

The more important question is whether monitoring effectively identifies risks affecting participant protection, protocol compliance and the reliability of critical trial data.

6. Technology Must Be Fit for Purpose

Technology is now embedded throughout clinical research.

A single study may involve:

E6(R3) recognizes this reality.

But adopting technology does not automatically improve quality.

Systems and processes need to be appropriate for their intended purpose.

This raises important considerations around:

System functionality
Validation
User access
Data security
Data integrity
Audit trails
System changes
Data transfer
Backup and recovery
Vendor oversight
Record retention

The question is therefore not:

“Are we using digital technology?”

It is:

“Can we trust the technology, processes and data for the purpose for which they are being used?”

Digital transformation without appropriate governance simply creates digital risk.

7. Data Governance Is Now Everyone's Business

Clinical trial data no longer originate solely from traditional case report forms.

Data may come directly from:

Participants
Investigators
Laboratories
Imaging providers
Wearable devices
Electronic health records
Electronic clinical outcome assessments
Third-party technology providers

As data sources diversify, responsibility for their integrity becomes increasingly important.

Trial teams need to understand:

Where did the data originate?

How were they captured?

Were they transformed?

Who had access?

How were changes controlled?

Can the data be reconstructed and interpreted?

This makes data governance a cross-functional responsibility involving clinical operations, data management, biostatistics, IT, quality, vendors and sponsors.

8. Sponsor Oversight Cannot Simply Be Outsourced

Modern clinical trials frequently rely on CROs and specialized service providers.

Sponsors may outsource:

Clinical monitoring
Data management
Pharmacovigilance
Biostatistics
Medical writing
Central laboratory services
Imaging
eClinical technologies
Site management

But outsourcing activities does not eliminate the need for appropriate sponsor oversight.

This makes vendor selection, qualification, governance and performance oversight increasingly important.

Effective oversight should include:

Clearly defined responsibilities
Appropriate communication pathways
Performance indicators
Risk escalation mechanisms
Quality expectations
Documentation
Issue management

The most successful sponsor-CRO relationships therefore operate as genuine partnerships with clear accountability—not simply transactional outsourcing arrangements.

9. Investigators and Sites Remain Central

Technology may change how trials operate, but investigators remain responsible for appropriate trial conduct at their sites.

Site teams need:

Adequate resources
Appropriate training
Clear delegation
Suitable facilities
Protocol understanding
Access to relevant study information
Effective safety processes

This also reinforces the importance of Clinical Research Coordinators (CRCs).

In many studies, CRCs are integral to day-to-day trial execution, participant communication, visit coordination and documentation.

A modern quality framework therefore requires us to consider not only whether the Principal Investigator is qualified, but whether the entire site research ecosystem is capable of delivering the protocol.

10. Participant Protection Remains the Foundation

With all the discussion surrounding risk management, technology and data, it is easy to lose sight of GCP's central purpose.

Clinical trials involve people.

Participants volunteer to contribute to research under conditions of uncertainty.

Their rights, safety and well-being therefore remain fundamental.

This includes:

Meaningful informed consent
Appropriate risk-benefit assessment
Privacy and confidentiality
Safety monitoring
Respect for participant autonomy
Appropriate communication of relevant information

E6(R3)'s modernization should not be interpreted as relaxing ethical expectations.

Quite the opposite.

The purpose of greater flexibility is to allow trial processes to focus resources where they best support participants and reliable evidence.

11. What About Decentralized Trials and Real-World Data?

This is particularly important in 2026.

E6(R3) has a modular structure comprising overarching Principles, Annex 1 and Annex 2.

In the EU, the Principles and Annex 1 became effective on 23 July 2025.

Meanwhile, Annex 2 addresses additional considerations for trials incorporating elements such as:

Decentralized clinical trial approaches
Pragmatic clinical trials
Real-world data sources

Annex 2 reached ICH Step 4 in June 2026 and has now been incorporated into the consolidated E6(R3) guideline. In the EU, Annex 2 is scheduled to become effective on 15 January 2027.

This distinction matters.

As of September 2026, organizations should understand both the GCP requirements already applicable under Principles and Annex 1 and the direction of travel represented by finalized Annex 2.

Modern GCP is clearly moving toward a framework capable of supporting diverse trial designs without compromising ethical standards or evidence reliability.

12. What Does E6(R3) Mean for CROs?

For CROs, E6(R3) should not be treated merely as another training module.

Its principles should influence how trials are actually planned and delivered.

That means asking questions such as:

Protocol Development:

Have we identified critical-to-quality factors early?

Feasibility:

Are operational assumptions realistic?

Clinical Operations:

Is monitoring aligned with actual study risk?

Data Management:

Are data flows understood and controlled?

Pharmacovigilance:
Are safety information and escalation pathways reliable?

Technology:
Are systems fit for their intended purpose?

Vendor Management:

Are responsibilities and oversight clearly defined?

Quality Assurance:

Are we preventing important problems rather than simply detecting them later?

This requires integration across functions.

Quality cannot belong only to the QA department.

Moving From Compliance to Quality Culture

Perhaps the most important lesson from E6(R3) is cultural.

There is a significant difference between:

“Are we compliant?”

and

“Is this trial designed and operated in a way that reliably protects participants and answers the research question?”

Compliance remains essential.

But genuine quality requires judgment.

It requires teams to understand why processes exist, which risks matter and when approaches need to adapt.

That is what a mature clinical research organization should strive toward.

The Agile Clinical Trendz Perspective

At Agile Clinical Trendz, we believe GCP should be embedded across the clinical trial lifecycle rather than treated as a standalone compliance exercise.

From protocol development and feasibility through clinical operations, site management, pharmacovigilance, data management, biostatistics, medical writing and quality assurance, every function contributes to trial quality.

The evolution represented by ICH E6(R3) reinforces a principle that should already sit at the heart of good clinical research:

Do not create complexity for the sake of demonstrating control.

Identify what matters. Understand the risks. Build quality into the study. Maintain appropriate oversight. Protect participants. Generate evidence we can trust.

Because Good Clinical Practice is ultimately not about producing perfect paperwork.

It is about conducting ethical, scientifically sound and reliable clinical research.

References

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline E6(R3): Guideline for Good Clinical Practice. Principles, Annex 1 and Annex 2.
European Medicines Agency. ICH E6 Good Clinical Practice – Scientific Guideline. Principles and Annex 1 effective 23 July 2025; Annex 2 effective in the EU from 15 January 2027.
U.S. Food and Drug Administration. E6(R3) Good Clinical Practice (GCP): Guidance for Industry. Final Level 1 Guidance. September 2025.
International Council for Harmonisation. ICH E8(R1): General Considerations for Clinical Studies. 2021.
World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. JAMA. 2025;333(1):71–74. doi:10.1001/jama.2024.21972.